Date: 2016-01-12
Type of information: R&D agreement
Compound: NeuroSTAT®
Company: Neurovive Pharmaceutical (Sweden) University of Pennsylvania (USA - PA)
Therapeutic area: Traumatology - CNS diseases
Type agreement: R&D collaboration
Action mechanism: immunosuppressive agent. The active ingredient cyclosporine acts by preventing the death of mitochondria in damaged cells and the following cascade of intracellular biochemical events that lead to secondary tissue damage. By protecting a cell\'s mitochondria, NeuroVive\'s products ensure that energy production is preserved and a damaged cell\'s normal regenerative mechanisms can act to repair and maintain the cell.
Disease: traumatic brain injury
Details: * On January 12, 2016, NeuroVive Pharmaceutical, the mitochondrial medicine company, announced that it has entered into a research partnership with University of Pennsylvania to enhance NeuroVive’s traumatic brain injury (TBI) research and development program. The research partnership will focus on nerve cell protection following moderate to severe brain trauma. The collaboration is to provide more data on NeuroVive’s drug for the treatment of TBI, NeuroSTAT®, and will provide the company with additional preclinical data to support the regulatory filings for the TBI indication. NeuroVive will, via this partnership, get access to highly experienced scientists at University of Pennsylvania and the Children’s Hospital of Philadelphia whom have world-renown expertise in the area of TBI research. Neurovive will work with Drs. Susan Margulies and Todd Kilbaugh at the University of Pennsylvania and the Children’s Hospital of Philadelphia. The company hopes to initiate the first studies during the first quarter of 2016. The agreement between University of Pennsylvania and NeuroVive represents the expanding footprint beyond Europe into the US and will further advance the company’s understanding of and presence in the US market.
Financial terms:
Latest news:
